Biotech Company** | Product | Pharma Partner | Type Arrangement/Geographic Area/ |
(Country) | (Country) | Details (Date) | |
Access | Aphthasol (amlexanox | Laboratorios Dr. | Letter of intent to license product for marketing in |
Pharmaceuticals | oral paste 5% for treat- | Esteve SA (Spain) | Italy, Spain, Portugal and Greece; Access gets up- |
Inc. (OTC Bulletin | ing aphthous ulcers; | front license fee, milestones and royalties (10/98) | |
Board:AXCS) | FDA-approved) | ||
Aphthasol (amlexanox | Meda AB (Sweden) | Letter of intent to license product for marketing in | |
oral paste 5% for treat- | Sweden, Finland, Norway, Denmark, Latvia, Estonia, | ||
ing aphthous ulcers; | Lithuania and Iceland; Access gets up-front | ||
FDA-approved) | license fee, milestones and royalties (10/98) | ||
Aronex | Nyotran (liposomal | Abbott Laboratories | Abbott gets worldwide marketing rights; Aronex gets |
Pharmaceuticals | formulation of Ny- | (NYSE:ABT) | $40M total ($2.85M up front, $3M in equity purchase |
Inc. | statin) for treating | [0.84M shares], milestones and development sup- | |
systemic fungal | port); Aronex also gets royalties; Abbott will fund | ||
infections (currently | continued clinical development; Aronex has option | ||
in pivotal Phase III | to co-promote in U.S. and Canada for at least 2 years; | ||
trials) | Abbott responsible for product registration outside | ||
U.S.; Abbott has manufacturing option (11/98) | |||
Avanir | N-docosanol 10% | Condea Chemie | Condea will manufacture active ingredient in prod- |
Pharmaceuticals | cream (long-chain | GmbH (Germany) | uct in sufficient quantities to meet product launch |
(formerly Lidak | fatty acid; topical) for | requirements (10/98) | |
Pharmaceuticals) | treating oral/facial | ||
herpes infections | |||
N-docosanol 10% | Bausch & Lomb Phar- | Bausch & Lomb will manufacture product; further | |
cream (long-chain | maceuticals (sub- | details ND (11/98) | |
fatty acid; topical) for | sidiary of Bausch & | ||
treating oral/facial | Lomb Inc.; NYSE:BOL) | ||
herpes infections | |||
N-docosanol 10% | Livingston Healthcare | Livingston will warehouse and distribute product if | |
cream (long-chain | Services Inc. | approved by FDA for marketing (11/98) | |
fatty acid; topical) for | |||
treating oral/facial | |||
herpes infections | |||
Biora AB | Emdogain (gel formu- | Seikagaku Corp. | Expansion of marketing agreement; Seikagaku |
(Sweden) | lation containing a | (Japan) | entered agreement with Yoshida Dental Trade to |
porcine protein that | broaden product's penetration of Japanese market | ||
mimics human protein | (12/98) | ||
amellogenin) for perio- | |||
dontal flap surgery | |||
Centocor Inc. | Retevase (reteplase; | DuPont Pharma- | Termination of co-promotion agreement on Retevase |
recombinant plasmino- | ceuticals Co. | (DuPont had preexisting contract with Roche Hold- | |
gen activator) for | (NYSE:DD) | ing Ltd., from which Centocor bought Retevase in | |
treating acute | 3/98); Centocor now has exclusive rights to market | ||
myocardial infarction | product in U.S., beginning 1/1/99 (12/98) | ||
Cephalon Inc. | Provigil (modafinil; oral | Merckle GmbH | Cephalon U.K. Ltd. licensed exclusive rights to |
formulation of synthetic | (Germany) | promote product in Austria and Switzerland in a | |
compound thought to | 10-year agreement (12/98) | ||
affect alpha-adrenergic | |||
receptors in brain) for | |||
treating narcolepsy | |||
Zeneca's Zomig (oral | Zeneca Group plc | Cephalon U.K. Ltd. will co-promote product in | |
treatment for migraine) | (NYSE:ZEN; U.K.) | U.K. (12/98) | |
CollaGenex | SmithKline's Denavir | SmithKline Beecham | CollaGenex will co-promote product to dental |
Pharmaceuticals | (penciclovir cream) | Consumer Healthcare | community in U.S. (10/98) |
Inc. | for treating recurrent | LP (unit of SmithKline | |
cold sores in adults | Beecham plc; | ||
NYSE:SBH; U.K.) | |||
Coulter | Bexxar (131-I-labeled | SmithKline Beecham | Potential value to Coulter is $132M, plus shared |
Pharmaceutical | murine monoclonal | plc (NYSE:SBH; U.K.) | profits and royalties; companies will jointly market |
Inc. | antibody against CD20 | product in U.S. and share profits equally; Smith- | |
antigen on B cells) for | Kline gets exclusive rights outside U.S., except in | ||
treating non-Hodgkin's | Japan; Coulter gets royalties; SmithKline gets | ||
lymphoma (pivotal | access to 2nd-generation anti-CD20 compounds; | ||
trials completed) | Coulter gets up-front payment of $41.5M (including | ||
$7.25M in equity), a $15M credit line, and $76M | |||
in regulatory and marketing milestones in other | |||
areas of world (12/98) | |||
Cytogen Corp. | Quadramet (samarium- | Berlex Laboratories | Marketing agreement; Berlex gets exclusive license |
153-EDTMP; isotope | Inc. (subsidiary of | to sell product in North and South America; Cyto- | |
concentrates in areas | Schering AG; | gen gets $8M up front on completion of supply | |
of new bone formation) | Germany) | agreement with DuPont (see below), of which it will | |
for treating pain asso- | pay $4M to DuPont; Cytogen also gets royalties on | ||
ciated with cancer that | net sales and milestones on preset sales levels; | ||
has spread to bone | Cytogen will complete Phase IV trials specified by | ||
(FDA-approved 3/97) | FDA; Berlex will fund clinical programs aimed at | ||
expanding current and additional product indications | |||
(10/98) | |||
Quadramet (samarium- | Berlex Laboratories | DuPont will supply product for 5 years as well as | |
153-EDTMP; isotope | Inc. (subsidiary of | continue to manufacture and distribute it; DuPont | |
concentrates in areas | Schering AG; | received $4M to secure long-term supply agree- | |
of new bone formation) | Germany) and | ment (11/98) | |
for treating pain asso- | DuPont Pharma- | ||
ciated with cancer that | ceuticals Co. | ||
has spread to bone | (NYSE:DD) | ||
(FDA-approved 3/97) | |||
Quadramet (samarium- | The Dow Chemical | Companies expanded 5/93 licensing agreement; | |
153-EDTMP; isotope | Co. (NYSE:DOW) | Cytogen, which previously had rights for this use in | |
concentrates in areas | North and South America only, now gains additional | ||
of new bone formation) | territories, including Europe and Japan; Berlex Lab- | ||
for treating rheumatoid | oratories Inc., which will market product (see above), | ||
arthritis (currently in | also holds license for these territories (12/98) | ||
Phase I trial) | |||
Epitope Inc. | OraSure oral specimen | STC Technologies | 5-year agreement; Epitope will be exclusive supplier |
collection device | Inc.* | of device for use with STC's lab-based tests for | |
drugs of abuse for sale in U.S. and Europe (exclud- | |||
ing U.K. and Ireland); STC will be exclusive distrib- | |||
utor in same territories; Epitope will sell devices to | |||
STC and gets a percentage of gross revenues (11/98) | |||
Genelabs | Vaccine for hepatitis | SmithKline Beecham | Expansion of SmithKline's marketing rights to |
Technologies Inc. | E virus infection | plc (NYSE:SBH; U.K.) | product (from 9/92 agreement); SmithKline gets |
exclusive (rather than co-exclusive) rights in Asia; | |||
Genelabs gets $1M payment; other terms remain | |||
unchanged (9/98) | |||
Guilford | Gliadel wafer (biode- | Rhone-Poulenc Rorer | Amendment of 6/96 marketing, sales and distribu- |
Pharmaceuticals | gradable polymer con- | Inc. (subsidiary of | tion agreement; companies will now share costs of |
Inc. | taining carmustine) for | Rhone-Poulenc SA; | single multinational Phase III trial of product for use |
treating brain cancer | NYSE:RP; France) | in 1st-line therapy for brain cancer (originally, each | |
firm was to conduct and pay for its own Phase III | |||
trial); Guilford will not pay more than $3M aggre- | |||
gate; Japanese rights have reverted back to Guil- | |||
ford; companies have also redefined international | |||
regulatory milestones (9/98) | |||
Hyal | Solarase (topical 3% | Fujisawa Healthcare | Letter of intent to license exclusive rights in U.S., |
Pharmaceutical | diclofenac gel) for | Inc. (U.S.; subsidiary | Canada and Mexico to Fujisawa; Fujisawa paid |
Corp. | treating actinic kera- | of Fujisawa Pharma- | $0.25M for 90-day period of exclusivity on option; |
(TSE:HPC; Canada) | tosis (precancerous | ceutical Co. Ltd.; | if deal is finalized, Hyal gets milestones and royal- |
skin lesions) | Japan) | ties (12/98) | |
Integra | Absorbable collagen- | Sulzer Calcitek Inc. | Expansion of product alliance; Sulzer has been |
LifeSciences Corp. | based matrices for use | (unit of Sulzer | exclusive distributor of Integra's dental surgery prod- |
in periodontics and | Medica; NYSE:SM) | uct line since 1992; alliance extended for 5 years | |
dental surgery | and expanded to include development of Integra's | ||
Biomend collagen matrix for guided tissue regenera- | |||
tion in periodontal surgery; Sulzer will fund devel- | |||
opment work (11/98) | |||
Megabios Corp. | DNA plasmids and | DSM Biologics | Companies will work together to create facility for |
lipid:DNA complexes | (Gist-Brocades/ | contract manufacturing of DNA plasmids and lipid: | |
Bio-Intermediair; | DNA complexes for the gene therapy industry; | ||
the Netherlands) | Megabios licensed its manufacturing technology to | ||
DSM; Megabios gets license fee and milestones; | |||
3-year exclusive partnership (9/98) | |||
Neoprobe Corp. | Neoprobe's gamma | CEI Ltda. (Brazil) | Partners get rights to distribute products in South |
detection products for | and Evergreen | America and China, respectively; both distributors | |
use in intraoperative | Enterprises Ltd. | will register products in respective territories (10/98) | |
lymphatic mapping | (People's Republic | ||
of China) | |||
Qiagen NV | Nucleic acid sample | Abbott Laboratories | 5-year supply agreement; Qiagen will supply Abbott |
(the Netherlands) | purification and prep- | (NYSE:ABT) | with its products, which Abbott will adapt for use in |
aration products (for | its LCx probe-based diagnostic system; Qiagen | ||
use in Abbott's molec- | retains rights to market products in all other formats | ||
ular diagnostics) | (10/98) | ||
Repligen Corp. | Amersham's recombi- | Amersham Pharma- | Repligen will be primary supplier of recombinant |
nant Protein A (binds | cia Biotech (joint | Protein A to Amersham Pharmacia Biotech for 10 | |
antibodies with high | venture of Nycomed | years; Repligen remains exclusive source of product | |
specificity) for use in | Amersham plc and | worldwide and retains all rights to commercialize | |
purification and manu- | Pharmacia & Upjohn | product for human therapeutics (12/98) | |
facturing of thera- | Inc.) | ||
peutic monoclonal | |||
antibodies and proteins | |||
Unimed | Cryptaz (NTZ; nita- | Romark | Unimed transferred development and marketing |
Pharmaceuticals | zoxanide) for treating | Laboratories | rights, plus associated know-how, to Romark, which |
Inc. | Cryptosporidiosis in | now has worldwide marketing rights; Unimed gets | |
AIDS | up-front payment and royalties on U.S. sales (11/98) | ||
Viragen Inc. | Omniferon (2nd-gen- | Southern Health | Southern Health obtained option to acquire exclu- |
eration, multi-species | SDN.BHD (Malaysia | sive private-label license to Viragen's production | |
natural alpha interferon | and Australia) | process for interferon in 4/98; it has now extended | |
derived from human | that option until 12/31/98 (10/98) | ||
white blood cells) | |||
Viragen Europe | Omniferon (2nd-gen- | AGC (Pakistan) | AGC will be exclusive supplier and distributor in |
Ltd. (NASDAQ:VERP; | eration, multi-species | Saudi Arabia, Kuwait, Yemen, Oman, United Arab | |
subsidiary of | natural alpha interferon) | Republic, Brunei and other Middle Eastern countries | |
Viragen Inc.) | for treating hepatitis B | as well as India and Pakistan; AGC will purchase | |
and C virus infections | minimum of $20M in product over 5 years, subject | ||
to regulatory approvals in its territories, where it | |||
is responsible for clinical and regulatory costs | |||
(11/98) | |||
NOTES: | |||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 9/23/98 and 12/24/98. | |||
ND = Not disclosed, reported and/or available; TSE = Toronto Stock Exchange | |||
* Private companies are indicated with an asterisk. | |||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 12-13. |